OAM
KRYS icon

Oppenheimer Asset Management’s Krystal Biotech KRYS Stock Holding History

Oppenheimer Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$259K Sell
696
-97
-12% -$29K ﹤0.01% 1030
2026
Q1 		$205K Sell
793
-251
-24% -$66.8K ﹤0.01% 1060
2025
Q4 		$257K Sell
1,044
-219
-17% -$46.1K ﹤0.01% 947
2025
Q3 		$223K Buy
+1,263
New +$189K ﹤0.01% 1070
2025
Q2 		– Sell
-1,269
Closed -$229K – 1186
2025
Q1 		$229K Buy
+1,269
New +$213K ﹤0.01% 1022
2024
Q4 		– Sell
-1,289
Closed -$235K – 1178
2024
Q3 		$235K Buy
+1,289
New +$249K ﹤0.01% 1056

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Oppenheimer Asset Management's KRYS Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Krystal Biotech (KRYS) stake by 12% in Q2 2026, selling an estimated $29K and leaving 696 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #1030.

Oppenheimer Asset Management first reported a position in KRYS in Q3 2024 and has held it in 6 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Oppenheimer Asset Management held 696 shares of Krystal Biotech worth $259K as of Q2 2026.
  • Oppenheimer Asset Management sold 97 Krystal Biotech shares in Q2 2026, an estimated $29K.
  • Krystal Biotech made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #1030 holding.
  • Oppenheimer Asset Management first reported a position in Krystal Biotech in Q3 2024 and has held it in 6 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.